Revenue Recognition and Collaborative Arrangements

3 Months Ended

Mar. 31, 2020

Revenue Recognition and Collaborative Arrangements

Revenue Recognition and Collaborative Arrangements

3. Revenue Recognition and Collaborative Arrangements

Net Revenue from Collaborative Arrangements

Net revenue recognized under our GSK Agreements was as follows:

	Three Months Ended March 31,
(In thousands)	2020		2019
Royalties from a related party - RELVAR/BREO	$	56,149	$	42,740
Royalties from a related party - ANORO		9,850		8,570
Royalties from a related party - TRELEGY		16,135		7,329
Total royalties from a related party		82,134		58,639
Less: amortization of capitalized fees paid to a related party		(3,456)		(3,456)
Royalty revenue from GSK	$	78,678	$	55,183